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Abstract
Background: For several decades now an antagonism between Trypanosoma cruzi infection and tumor development
has been detected. The molecular basis of this phenomenon remained basically unknown until our proposal that T. cruzi
Calreticulin (TcCRT), an endoplasmic reticulum-resident chaperone, translocated-externalized by the parasite, may mediate
at least an important part of this effect. Thus, recombinant TcCRT (rTcCRT) has important in vivo antiangiogenic and
antitumor activities. However, the relevant question whether the in vivo antitumor effect of T. cruzi infection is indeed
mediated by the native chaperone (nTcCRT), remains open. Herein, by using specific modified anti-rTcCRT antibodies
(Abs), we have neutralized the antitumor activity of T. cruzi infection and extracts thereof, thus identifying nTcCRT as a
valid mediator of this effect.
Methods: Polyclonal anti-rTcCRT F(ab’)2 Ab fragments were used to reverse the capacity of rTcCRT to inhibit EAhy926
endothelial cell (EC) proliferation, as detected by BrdU uptake. Using these F(ab’)2 fragments, we also challenged the
capacity of nTcCRT, during T. cruzi infection, to inhibit the growth of an aggressive mammary adenocarcinoma cell line
(TA3-MTXR) in mice. Moreover, we determined the capacity of anti-rTcCRT Abs to reverse the antitumor effect of an
epimastigote extract (EE). Finally, the effects of these treatments on tumor histology were evaluated.
Results: The rTcCRT capacity to inhibit ECs proliferation was reversed by anti-rTcCRT F(ab’)2 Ab fragments, thus defining
them as valid probes to interfere in vivo with this important TcCRT function. Consequently, during infection, these Ab
fragments also reversed the in vivo experimental mammary tumor growth. Moreover, anti-rTcCRT Abs also neutralized the
antitumor effect of an EE, again identifying the chaperone protein as an important mediator of this anti mammary tumor
effect. Finally, as determined by conventional histological parameters, in infected animals and in those treated with EE,
less invasive tumors were observed while, as expected, treatment with F(ab’)2 Ab fragments increased malignancy.
Conclusion: We have identified translocated/externalized nTcCRT as responsible for at least an important part of the anti
mammary tumor effect of the chaperone observed during experimental infections with T. cruzi.
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Background
In this report, we identify a protein from the Trypanosoma
cruzi (the protozoan agent of Chagas disease) endoplasmic
reticulum (ER), as responsible for, at least an important
part of the antitumor effect of this infection.
Chagas’ disease (American Trypanosomiasis) is mainly
spread by Triatominae insects. Originally confined to
America, the disease has now gone global [1].
Only 30 % of T. cruzi infected people presents variable
symptoms, years or decades after infection [1], thus indicat-
ing that the protozoan components, as occurs in many par-
asitisms, are relatively well tolerated during the infection.
Interestingly, several reports indicate that in patients
with Chagas’ disease cancer is an extremely rare event, in
particular breast adenocarcinomas. Thus, about 80 years
ago, Roskin, Ekzempliarskaia and Klyuyeva, researchers
from the former Soviet Union, postulated an experimental
anticancer toxic activity derived from this infection. When
they inoculated T. cruzi extracts, directly in a peritumoral
area, in different tumors, both in experimental animals
and in humans, similar results to those obtained with the
infection were generated. Moreover, the parasite capacity
to infect preferentially tumor cells, as compared to normal
host cells, was also described (reviewed in [2]). Although,
in general, these data suggest an antagonism between T.
cruzi infection and tumor growth [3], research progress in
these areas was seriously hampered by the intense inter-
national political problems of those years (i.e. the Cold
War) [4, 5]. Although several publications on these issues
have appeared during the last decade [3, 6–8], the molecu-
lar basis of this phenomenon has remained elusive.
Our laboratory interest in understanding molecular terms
ruling the host/parasite interplay has led us to the identifi-
cation, sequencing, cloning, expression and characterization
of a 45 kDa protein, T. cruzi Calreticulin (TcCRT), an
ER-resident chaperone [9–14]. We have described three
domains in recombinant TcCRT (rTcCRT): N-terminal
(N-TcCRT) (aa 120–180), with antiangiogenic activity
[9, 15]; central-S (aa 159–281), that binds and inhibits
human C1, the first component of the complement sys-
tem, [16] and, P (aa173–286), mainly involved in calcium
binding [16].
Most important, during infection TcCRT is exterior-
ized from the ER to the area of flagellum emergence
[16]. We have shown that rTcCRT inhibits angiogenesis
(in vitro, ex vivo, in ovum and in vivo) in three verte-
brate species (Rattus rattus, Gallus gallus and Homo
sapiens sapiens) [9, 15, 17], and that it interferes with
morphogenesis, migration and proliferation of endo-
thelial cells (ECs) [9]. When ECs were incubated with
rTcCRT, we observed that the protein was internal-
ized. This internalization is inhibited by fluid-phase
Fucoidan [9, 10], a sulfated polysaccharide and ligand
for Scavenger Receptors (SR) [18].
The parasite cycle in the mammal host implies that, from
the original infection site caused by the hematophagous
arthropod vector, T. cruzi must access the circulation in
order to reach its target tissues (mainly heart, esophagus,
colon and aorta) [1]. Once in the circulation, the parasite
must swiftly contact the ECs apical membrane surface. In
this key step and since ECs display receptors (cC1qR) for
complement component C1 [19, 20], a synapse will be
formed by parasite TcCRT, host C1 and EC (host) CRT
(cC1qR) (reviewed in [2]). Alternatively or concomi-
tantly, T. cruzi ability to contact and infect ECs may in-
volve direct interaction of TcCRT with a constitutive
SR present on ECs [21–23].
rTcCRT, inoculated in a peritumoral area, reduced the
growth of an aggressive, multiresistant mammary adeno-
carcinoma (TA3-MTXR) in mice [9]. The rTcCRT antian-
giogenic activity and antitumor effects were more efficient
than those mediated by human CRT (rHuCRT), when
compared at equimolar concentrations [9, 17].
However, these facts do not necessarily mean that
native parasite CRT (nTcCRT), indeed mediates the
infection antineoplastic effect. This important ques-
tion is justified by the following rationale: i). The
possibility exists that one or several, still unidentified
parasite molecules, could largely mediate the import-
ant antitumor effects observed during T. cruzi infec-
tion (or after injection of parasite lysates); ii). Given
the cloning procedures, recombinant (rTcCRT) used
in vivo in the previously reported experiments [14], is
structurally different from the native version operating
during infection (e.g.: addition of a polyhistidine tail,
lack of glycosylations, marginal LPS contamination,
protein degradation, among other possibilities); iii).
The experimental conditions of the reported in vivo
treatment of tumor-bearing animals with rTcCRT [9]
(i.e. the protein is injected several times in peritumor
sites) are radically different from those mediated by an
experimental or natural infection with the parasite
and, iv). CRTs from different species were traditionally
located in the ERs, and all of them carry a carboxi-
terminal ER-retention signal (KDEL, in TcCRT) [19, 24].
Although nTcCRT is translocated to the parasite area of
flagellum emergence [15], we have no firm vidence that
the chaperone can diffuse to the surrounding fluid phase.
Antibody (Ab) -targeted neutralization of its antitumor
effects during infection is thus informative with regard to
this important function.
Herein, we propose that, during T. cruzi infection, the
responsible antitumor molecule is nTcCRT expressed by
the parasite. We have been able to revert the antitu-
mor effect of the infection by targeting nTcCRT with
specific Abs, among the multitude of parasite mole-
cules present in the infecting parasite (or extracts
thereof ).
Abello-Cáceres et al. BMC Cancer  (2016) 16:731 Page 2 of 12
Methods
Reagents, recombinant proteins and Abs
rTcCRT and its N-TcCRT domain, rabbit whole anti-
rTcCRT Abs, their preimmune counterparts, as well as
their F(ab’)2 fragments, were all generated, in our labora-
tory, by immunizing rabbits with the pure recombinant
molecule, by standard procedures [9, 15, 25]. All these Abs
were monospecific since, in immunowestern assays they
recognized only nTcCRT in whole T. cruzi extracts. The ra-
tionale for choosing whole anti-rTcCRT Abs or their F(ab’)2
fragments, in the experiments described below, is examined
in the Discussion section.
Capacity of F(ab’)2 anti-rTcCRT Ab fragments to prevent
the chaperone binding to human ECs
The experimental design aimed at studying the capacity
of anti-rTcCRT F(ab’)2 Ab fragments to neutralize the
interaction of the parasite chaperone with human ECs.
Two types of Fucoidan were used as positive controls
[9]. First, 2x105 ECs (EAhy926) [26] (donated by Dr.
Gareth Owen, Pontifical Catholic University of Chile),
were seeded in IMDM (Iscove’s Modified Dulbecco’s
Medium, Invitrogen, USA). The medium was supple-
mented with 10 % v/v heat-inactivated fetal bovine serum
(FBS, Invitrogen, USA), 1 % penicillin/streptomycin (Sigma,
USA), 1 % glutamine (Invitrogen, USA) and sodium bicar-
bonate 0.3 M (MERCK, Germany). The cells were collected
at 80 % confluence and expanded. rTcCRT was coupled to
FITC (F-rTcCRT) according to manufacturer’s instructions
(FluoReporter FITC Protein Labeling Kit, Molecular
Probes, USA).
Later, in eight in vitro experimental groups, 3×105
EAhy926 cells were incubated in 96-well flat bottom
plates, for 6 h, at 37 °C, adding: i.) F-rTcCRT (1 μM); ii.)
F-rTcCRT with anti-rTcCRT F(ab’)2 fragments (120 μg); iii.)
F-rTcCRT and preimmune Ab fragments; iv.) F-rTcCRT,
with Fucoidan 1 (Mw= 20–200 kDa) (Sigma-Aldrich, USA)
(100 μg); v.) F-rTcCRT, with Fucoidan 2 (Mw= 58.6 kDa)
(Sigma-Aldrich, USA) (100 μg); vi.) N-rTcCRT; vii.) N-
rTcCRT with Fucoidan 1 and, viii.) N-rTcCRT with
Fucoidan 2.
After 6 h incubations, the cells were analyzed by flow
cytometry (BD FACSAria III) (20.000 events) using the
software FCS Express 5.
Capacity of F(ab’)2 anti-rTcCRT Ab fragments to revert the
rTcCRT-dependent inhibition of EC proliferation
The EAhy926 cells origin, culture and harvesting conditions
were described above. Reversion of the anti-proliferative
rTcCRT effect on ECs was detected by BrdU uptake (BrdU
Cell Proliferation Assay Kit, Millipore© cat. 2750). Briefly,
3×104 ECs were incubated in 96-well flat bottom plates
(Nunc, UK), for 24, 48 and 72 h. ECs were the incubated
with rTcCRT (1 μM) and/or 80 μg in 200 μl of F(ab’)2
fragments (anti-rTcCRT or preimmune controls). Re-
sults were expressed as percentage compared to the
control group (100 % proliferation).
Tumor, induction and evaluation
The methotrexate (MTX)-resistant (MTXR) cell line
(TA3-MTXR) [27], was originally isolated from the TA3
mammary adenocarcinoma, grown as ascites by weekly
i.p. injections of 106 cells into histocompatible mice [28].
The TA3-MTXR mammary tumor cell line was generated
by weekly consecutive selection in the presence of MTX
[28]. The tumor cells TA3-MTXR used herein were ex-
tracted from mouse ascites, diluted in physiological saline
solution and centrifuged at 423G for 5 min at room
temperature. The supernatant was discarded and the pel-
let was suspended in physiological saline, and counted in a
Neubauer chamber. Over 95 % tumor cell viability was
routinely obtained.
In all experiments, mice were inoculated s.c. on the
supra scapular region, with 5×105 TA3-MTXR, freshly
obtained mammary tumor cells, contained in 100 μl.
Evaluation of tumor growth was blindly monitored, for
30 days [11] and, in compliance with bioethical regula-
tions, until they reached a maximum of 3.000 mm3, when
the animals were euthanized. In each test, the minimum
number of animals per experimental group was eight, un-
less otherwise defined, a calculation based on mean values
and their standard deviations, obtained in previous experi-
ments [29].
Immune mediated specific reversion of the antitumor
effects of rTcCRT
Five experimental groups were designed. All of them were
inoculated with the TA3-MTXR tumor cells. In addition
the animals were treated as follows: Group I: PBS, as posi-
tive control (s.c.); Group 2: rTcCRT (50 μg, s.c.); Group 3:
In order to reverse the rTcCRT antitumor capacity,
this group was inoculated with whole anti-rTcCRT Abs
(500 μg); Group 4: As a negative control these mice re-
ceived preimmune Abs and, Group 5: N-rTcCRT.
All inoculations were performed every other day on a
peritumor area.
Immune mediated specific reversion of the antitumor
effects of a trypomastigote infection
Four experimental groups were designed. All of them
were inoculated with the TA3-MTXR tumor cells. In
addition the animals were treated as follows: Group I:
PBS, as positive control (i.v); Group 2: Mice were in-
fected i.p. with 103 trypomastigotes (infective form) of
the Tulahuén strain; Group 3: In order to reverse the
antitumor capacity of the infection, mice were also inocu-
lated, in the lateral tail vein, with F(ab’)2 anti-rTcCRT Abs
(200 μg in 100 μl) and, Group 4: As a negative control,
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these mice received preimmune F(ab’)2 Abs. All groups
were inoculated with TA3-MTXR tumor cells on day 8,
corresponding to the parasitemia peak.
Immune mediated specific reversion of the antitumor
effects of an epimastigote extract
Epimastigotes are T. cruzi non-infective forms, obtained
from axenic cultures [30]. They express nTcCRT, although
their capacity to translocate the chaperone to the area of
flagellum emergence is absent or marginal [31]. We first
asked whether an epimastigote extract (EE) reproduces
the in vivo antitumor effect of infective trypomastigotes
and if this effect is inhibited by whole anti-rTcCRT Abs,
based on the rationale described at the beginning of this
section. The Tulahuén clone (donated by Dr. Juan Diego
Maya, ICBM, Faculty of Medicine, University of Chile),
was grown at 28 °C in modified Diamond’s medium [30]
and 2×106 parasites were used to prepare the EE, by
standard procedures [32].
Four experimental groups were designed. All of them
were inoculated with the TA3-MTXR tumor cells. In
addition, the animals were treated as follows: Group I: PBS,
as positive control (s.c.); Group 2: EE, s.c.; Group 3: In
order to reverse the antitumor capacity of EE, this group
was inoculated with whole anti-rTcCRT Abs (200 μg);
Group 4: As a negative control these mice received pre-
immune Abs.
All inoculations were performed every other day on a
peritumor area.
Immune mediated specific reversion of the antitumor
effects of trypomastigote infection or epimastigote
extract, as assessed by histopathology
Tumors were extracted and fixed with 10 % formalin for
48 h, dehydrated and clarified [11]. The sections were em-
bedded on paraffin (Paraplast Plus®, Sigma-Aldrich, USA)
and 4 μm thick slices were stained with Hematoxylin-
Eosin, and mounted with Entellán®. A description of the
main lesions observed in the tumor samples was performed
on 10 fields of 40 and 400× zoom, in an Olympus FS100
microscope.
Statement of bioethical approval
Our Institutional Bioethics Committee approved the
experimental protocols using animals. Eight to 12-week-
old female A/J mice were maintained under internation-
ally accepted guidelines in our Animal Facility (Faculty
of Medicine, University of Chile).
Statistical analyses
When pertinent, experimental data were statistically
validated by One or Two-Way ANOVA and post-hoc
Bonferroni’s Multiple Comparison and also by one-tailed
Wilcoxon Signed-Rank, using the software GraphPad
Prism 5.
Results
rTcCRT and its N-domain interactions with ECs can be
interfered with Abs or Fucoidan
rTcCRT contact with ECs is a prerequisite for the inhib-
ition of cell proliferation and migration, two crucial events
in angiogenesis [9]. Most likely rTcCRT interacts with SRs
present on human ECs [21–23]. In such a case, Abs
against rTcCRT or, fluid-phase Fucoidans (specific SR li-
gands), should interfere with the EC/rTcCRT interaction
in vitro. Figure 1a, c show typical flow cytometry analyses,
while Fig. 1b, d, summarize their respective statistical vali-
dations. Figure 1a shows that anti-rTcCRT F(ab’)2 frag-
ments inhibit the F-rTcCRT/EC interaction (p < 10−4).
Figure 1c shows that two types of Fucoidans do interfere
with this interaction (p < 10−4), as valid positive controls.
The F-N-rTcCRT interaction with ECs was similarly
inhibited by Fucoidan 1 and Fucoidan 2 (p < 0.05, in both
cases). Moreover, and as expected, F-rTcCRT and F-N-
rTcCRT interactions with ECs were similar (Fig. 1e-f).
Whole anti-rTcCRT Abs and their F(ab’)2 fragments abrogate
the rTcCRT-dependent inhibition of EC proliferation
Since, as shown above, rTcCRT interaction with ECs is
reversed by anti-rTcCRT Abs (and also by fluid-phase
Fucoidans), we asked whether these Abs also abrogate
the chaperone capacity to inhibit EC proliferation. We
determined that, while the F(ab’)2 Ab fragments inhib-
ited ECs proliferation at 24, 48 and 72 h of incubation
(p < 0.001, in all cases), the inhibitory capacity of their
whole counterparts was detectable only at 48 and 72 h
(p < 0.05 and p < 0.01, respectively) (Fig. 2). Since these
experiments were conducted in the absence of C1, it is
then possible that these Abs interfere with the rTcCRT
capacity to interact with SRs present on ECs.
Immune mediated specific abrogation of the anti
mammary tumor effects of rTcCRT
If the in vivo antitumor effect of T. cruzi infection is indeed
mediated by translocated/exteriorized nTcCRT [16], this
effect should be reversed by anti-rTcCRTAbs. We first vali-
dated these Abs with regard to their capacity to revert the
antitumor effect of rTcCRT, already reported by our labora-
tory [[9–12]. Indeed, this property was abrogated by these
Abs, and tumor growth reached levels similar to those of
the negative control group (Fig. 3a). (Noteworthy, this
experiment also confirms the potent antitumor effect re-
ported for rTcCRT [9, 11], used here as a positive control).
Additionally and as expected, the N-rTcCRT domain main-
tains the antitumor effect of its whole counterpart, as
shown in Fig. 3b.
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Specific anti-rTcCRT Abs abrogate the mammary antitumor
effects of T. cruzi infection
The rationale for choosing F(ab’)2 Ab fragments to revert
the antitumor effects of a trypomastigote infection is based
mainly on the fact that T. cruzi translocates its TcCRT to
the area of parasite flagellum emergence, where it binds
complement C1 [15, 33]. The Fc-dependent IgG capacity of
whole anti-rTcCRT Abs to recruit additional C1 is absent
in F(ab’)2 fragments; thus these fragments block infectivity
[25, 33] and possibly the parasite antitumor properties. We
therefore propose that this T. cruzi translocated nTcCRT
contacts ECs, thus exerting an antiangiogenic effect,
Fig. 1 The interaction of rTcCRT and its N-domain with ECs can be intervened by Abs or Fucoidan. Using flow cytometry, human ECs (EAhy926)
were incubated with F-rTcCRT in the presence of: a Anti-rTcCRT F(ab’)2 fragments or their preimmune counterparts; c Fucoidans 1 or 2. EAhy926
cells were also incubated with: e F-N-rTcCRT or alternatively with F-N-rTcCRT and Fucoidans 1 or 2. Statistical validation: b d and f (One-Way
ANOVA and a post-hoc Bonferroni’s multiple comparison test
Fig. 2 Whole anti-rTcCRT Abs and their F(ab’)2 fragments revert the rTcCRT-dependent inhibition of EC proliferation. Human ECs (EAhy926) were
incubated with rTcCRT, in addition to whole anti-rTcCRT Abs, their respective F(ab’)2 fragments or the preimmune counterpart of each Ab type.
Proliferation was analyzed by incorporation of BrdU and expressed as percentage, where 100 % corresponds to cells incubated with medium
alone (Two-Way ANOVA and a post-hoc Bonferroni’s multiple comparison test)
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followed by inhibition of tumor growth. In fact, those
animals inoculated with anti-rTcCRT F(ab’)2 fragments
showed an inhibition of the antitumor effect associated
with this infection (Fig. 4). We have thus established a
causal relationship between parasite nTcCRT and the
antitumor effect of this infection.
An epimastigote extract displays an anti mammary
tumor effect that can be also reversed by specific
anti-rTcCRT Abs
The original experiments of Roskin and Klyuyeva included
the direct inoculation, at the tumor site, of a lysate of blood
trypomastigotes, with antitumor consequences (reviewed in
[2]). We used EE (prepared with non-infective parasites) in-
stead, that displayed a single band, compatible with
nTcCRT, when detected with specific polyclonal and mono-
clonal Abs, in conventional immunowesternblotting [34].
We inoculated the animals with whole anti-rTcCRT Abs,
aiming at neutralizing the EE parasite protein capacity to
inhibit tumor growth.
As predicted, in the EE-treated group, smaller tumor
sizes and even full tumor regression was observed.
When anti-rTcCRT Abs were inoculated, this EE effect
was statistically reversed (Fig. 5).
Fig. 3 The anti mammary tumor effect of rTcCRT is reversed by whole anti-rTcCRT Abs and the N-rTcCRT domain retains the effect of the
full recombinant protein. A/J mice were inoculated s.c., in a supra escapular area, with mammary adenocarcinoma cells (TA3-MTXR, control
group) and challenged as indicated in the Figures and detailed in the Materials and Methods section. a Reversion of the rTcCRT antitumor
effect; b N-rTcCRT antitumor effect. Recombinant proteins and Abs were delivered every other day. (One-tailed Wilcoxon signed-rank test)
Fig. 4 The anti mammary tumor effects of T. cruzi infection is reversed by specific anti-rTcCRT F(ab’)2 fragments. A/J mice were inoculated s.c. in a
supra escapular area with mammary adenocarcinoma cells (TA3-MTXR, control group) and challenged as indicated in the Figure and detailed in
the Materials and Methods section. In all cases the infection with T. cruzi was performed 8 days before the inoculation of tumor cells, and the delivery
of Abs was performed every other day. (One-tailed Wilcoxon signed-rank test)
Abello-Cáceres et al. BMC Cancer  (2016) 16:731 Page 6 of 12
Mammary tumors grown in animals alternatively treated
with T. cruzi infection, EE or N-rTcCRT, display a less
aggressive histological pattern
Mammary tumors, in untreated groups, showed more
aggressive histological patterns, with changes at the deep
dermal levels (vascularization, edema, inflammation and
congestion), with areas of high tumor cell proliferation
that profusely invaded the dermal layers (Fig. 6a). Notably,
in these untreated animals, tumor cells displayed a less co-
hesive pattern, with infrequent contacts among them and
with a high nucleus/cytoplasm ratio (Fig. 6b). Moreover, a
high percentage of bizarre, both multinucleated or mitotic
cells, was observed, as well as tumor cells that invaded the
dermis and epidermis causing, in some cases, ulceration
of the skin surface (Additional file 1: Fig. S1A-D).
On T. cruzi infected animals, we found more conserved
and differentiated tumor cells, distributed as large sheets
of cells in a more compact arrangement, with bigger and
vacuolated cytoplasm (Fig. 6d). These samples were less
invasive towards adipose tissue and most samples pre-
sented defined and encapsulated internal margins, without
subcutaneous invasion (Fig. 6c). A similar situation was
observed in animals inoculated with EE and N-rTcCRT
(Fig. 6g–j). However, when the animals were treated with
anti-rTcCRT F(ab’)2 fragments, this pattern was not main-
tained and tumor histopathology was very similar to the
control group (Fig. 6e–f ).
Discussion
We have proposed that rTcCRT [13, 14] provides an
important at least partial explanation of why T. cruzi ex-
perimental infection or the inoculation of parasite extracts
exerts toxic effects on different tumor types, mammary
adenocarcinoma among them (reviewed in [2]).
We have described a 45 kDaT. cruzi, highly pleiotropic
chaperone protein, TcCRT [13]. rTcCRT [13] is antian-
giogenic because it inhibits ECs proliferation, migration
and morphogenesis, in several in vitro, ex vivo and in vivo
assays, in 3 species, H. s. sapiens included [9, 16, 17].
Furthermore, in vivo, rTcCRT inhibits the growth of an
experimental mammary adenocarcinoma, when inoculated
in an area near the tumor. This effect is more potent than
the one elicited by its rHuCRT counterpart [9]. However,
the proposal that T.cruzi infection has an antitumor effect
mediated by its nTcCRT, needs a formal demonstration, as
justified in the Introduction section. This important ques-
tion was addressed herein. In order to causally implicate
nTcCRT in the antitumor effect of T. cruzi infection, we
blocked these effects, with polyclonal anti-rTcCRT Abs, in
the context of the trypomastigote infection or epimastigote
extract (EE) inoculation. Since angiogenesis is important
for tumor development, we previously showed that these
Abs neutralize the antiangiogenic effect of rTcCRT [17].
We first checked whether anti-rTcCRT Abs block the
chaperone binding to ECs [9], since this contact is a neces-
sary prerequisite for angiogenesis inhibition. As expected,
anti-rTcCRT F(ab’)2 fragments reversed this interaction
(Fig. 1a-b), as well as the antiproliferative effect reported for
rTcCRT [9] (Fig. 2). Thus, we validated these Abs for their
use in vivo.
The rationale for choosing whole anti-rTcCRT Abs or
their F(ab’)2 fragments, in the experiments described below,
is based on their differential Fc-dependent capacity to bind
human complement C1 [25, 33] Thus: i). Whole anti-
rTcCRT Abs, upon recognizing translocated nTcCRT on
trypomastigotes, will recruit host C1, a potent infectivity-
promoter [33]; ii). Because this Fc-dependent C1-recruiting
IgG capacity is absent in F(ab’)2 fragments, these will block
infectivity [33]; iii). Contact of rTcCRT with C1 and/or
membrane receptors, and its functional consequences,
should be blocked with both whole IgG or F(ab’)2 frag-
ments [33] and, iv). nTcCRT, present in a non-infective
EE [34] should be also blocked by both whole IgG or
F(ab’)2 fragments (Figs. 5 and 4, respectively).
A possible mechanism favoring the rTcCRT EC internal-
ization [9] involves its binding to Scavenger Receptors
(SRs). nTcCRT has affinity for collagenous structures, thus
explaining its binding to human C1, with consequent inhib-
ition of the classical pathway of the complement system
[15, 33]. Fluid-phase Fucoidan, bearing extensive collagen-
Fig. 5 The anti mammary tumor effect of an epimastigote extract (EE) is reversed by specific anti-rTcCRT Abs. A/J mice were inoculated s.c. in a
supra scapular area with mammary adenocarcinoma cells (TA3-MTXR, control group) and challenged as indicated in the Figure and detailed in
Materials and Methods. The EE anti mammary tumor effect is reverted by specific anti-TcCRT Abs. (One-tailed Wilcoxon signed-rank test)
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like sequences, inhibits the binding of CRT to SR-A,
present on phagocytic cells [18], and the internalization
of rTcCRT by ECs [9]. In agreement with these find-
ings, the two types of Fucoidans used by us, inhibited
the binding to ECs of both rTcCRT (Fig. 1c-d) and its
N-domain (Fig. 1e-f ).
Since SR-A1 has a high proportion of collagenous se-
quences [22, 23], the possibility exists that rTcCRT exerts
its action via EC internalization through this SR [21–23].
The relevant signaling pathways and activated or inhibited
genes are still unknown.
Since anti-rTcCRT Abs abrogated the antitumor effect
of rTcCRT [9–11] (Fig. 3a), it could be proposed that
they should block the native parasite protein, in the con-
text of an infection or EE inoculation.
We next asked whether antiangiogenesis has implica-
tions in the antitumor capacity of the parasite chaperone.
We showed that the N-domain (antiangiogenic) [9] effect-
ively inhibited tumor development (Fig. 3b), thus opening
the probability that even smaller subdomains, still to be
defined, may also exert this effect.
However, the facts that, on the one hand, T. cruzi in-
fection has an antitumor effect [2–5] and, on the other,
rTcCRT largely reproduces it [9], does not necessarily
mean that, during infection, nTcCRT is indeed a valid
mediator of this effect. As expected, anti-rTcCRT (Fab’)2
Abs inhibited this antitumor effect (Fig. 4), thus formally
involving nTcCRT.
Roskin and Klyuyeva injected, directly into the tumor site,
parasite lysates with antitumor effects (reviewed in [2]). Epi-
mastigotes, non-infective T. cruzi forms, express marginal
levels of TcCRT on their external membrane [31], although
intracellular levels of the chaperone are apparently normal.
TcCRT translocation in these parasite forms is apparently
Fig. 6 Mammary tumors from animals treated with either T. cruzi infection, EE or N-rTcCRT, display less aggressive histological patterns. TA3-MTXR
tumor (T) extracted from representative animals: a b Non infected, control group; c d T. cruzi infected; e f T. cruzi- infected, inoculated with anti-rTcCRT
F(ab’)2 fragments; g h Inoculated with an EE; i j Inoculated with N-rTcCRT. The following parameters were analyzed: E: Epidermis; D: Dermis layer; T:
Tumor tissue (a, c, e, g, and i) and TC: Tumor cells (b, d, f, h and j)
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deficient [31] and may explain, at least partly, their incap-
acity to infect cells. As expected, EE delayed tumor growth
and, in some animals, complete tumor regression was ob-
served (Fig. 5). A recent report [6] shows similar results, in
a rat model. Indeed, they reproduce the antitumor effects
of T. cruzi epimastigote lysates and found that they trigger
cytotoxic responses against tumors, with activation of both
CD4+ and CD8+ T cells. These extracts elicited the pro-
duction of antibodies that cross reacted with human
colon and breast cancer tissue samples. Given our re-
sults, most likely the antitumor effect observed by these
authors should be significantly and specifically inhibited
by our anti-rTcCRT Abs, as shown in Fig. 5. In synthesis
and in agreement with the previous results, T. cruzi infec-
tion effects on the normal course in a mammary tumor
development is largely nTcCRT-dependent.
Representative tumor histology indicated decreased
tumor malignancy, in particular at 28 d.p.i. Noteworthy,
in T. cruzi infected animals, or EE or N-TcCRT inocu-
lated ones, tumors were encapsulated and less invasive
(Fig. 6c-d, g–j). In agreement with the previous results,
when, in infected animals, TcCRT was blocked with
F(ab’)2 anti- TcCRT Ab fragments, more aggressive
tumor patterns are observed (similar to the control
group) (Fig. 6a-b, as compared to Fig. 6e-f ).
Altogether, these results support the antitumor activity
of nTcCRT, although we cannot completely rule out the
involvement of other parasite molecules.
The use of a recombinant nonpathogenic T. cruzi clone
as a vaccine vector to induce T-cell-mediated immunity has
been reported [35]. These authors show that transgenic
parasites, expressing a cancer testis antigen, elicit human
antigen-specific T-cell responses in vitro and protection
against a murine melanoma in vivo. Given our results, in
this work it would have been important to define whether
the nonpathogenic T. cruzi clone used by these authors
translocates-externalizes its CRT. As mentioned above,
non-infective epimastigotes are strongly impaired in their
capacity to translocate this chaperone [31]. Moreover,
hemiallelic TcCRT KO, wild type and transgenic parasites
respectively carrying one, two and three TcCRT gene copies,
express increasing levels of the protein. As expected, these
facts positively correlate with increased in vitro resistance
to human complement, as well as with infectivity [36, 37].
We will soon test these three clones in their experimental
capacity to control tumor growth.
Although we cannot rule out a role of antitumor innate
immunity in the results presented herein, during infection
TcCRT seems to be playing a direct immunogenic role in
the induction of specific anamnestic immunity against the
experimental mammary tumor tested. Human complement
component C1 plays an extremely important adjuvant role
by generating potent opsonizing signals on the parasite
[33, 38], thus increasing their infectivity. Preliminary
results from our laboratory, show increased numbers of
CD8+ and CD4+ lymphocytes in rTcCRT-treated mam-
mary tumor bearing mice. Again, concomitant import-
ant decreases in tumor sizes were observed (Gallardo et
al., 2016, unpublished).
In synthesis, as depicted in Fig. 7, we can propose that
T. cruzi infection mediates key alterations in the tumor
cell microenvironment that may lead to an adaptive
immune response, with significant antitumor effects.
Once in the circulation, T. cruzi must swiftly invade
ECs. Translocated-exteriorized TcCRT [15] will recruit
and inactivate plasma complement C1. This will allow
the parasite to contact ECs via cC1qR [19, 20]. Otherwise,
the chaperone protein could interact directly with SR-A1
on ECs [21–23]. Both pathways may lead to antiangiogen-
esis and generate a stressful environment where tumor cells
will externalize their CRT, as previously shown with other
stressing agents, such as antracyclins [39]. Complement C1
recruitment and increased tumor cell phagocytosis by den-
dritic cells will follow.
On the other hand, an adaptive immune response may
involve both highly immunogenic rTcCRT, and its native
counterpart, this one present on the membrane of infect-
ing trypomastigotes [15] or in EE [32, 34]. In any case, the
chaperone protein should reach the surface of both
endotheliocytes and tumor cells, thus generating a site for
C1 binding. Tumor cells, thus opsonized should be
phagocytized by dendritic cells. Upon arrival to the re-
gional lymph nodes, these dendritic cells will present
antigenic peptides derived from TcCRT, thus activating
cytotoxic T lymphocytes. Whether tumor cells can cross-
present peptides derived from endocytosed TcCRT to
cytotoxic T cells, is a matter of current research in our
laboratory. Activated cytotoxic T cells should then return to
the tumor site and act against neoplastic tumor cells in
both, primary, as well as in metastatic foci (Fig. 7), a mech-
anism already shown for whole EE [40].
Because about 90 % identity exists among mammal
CRTs, while TcCRT is only 50 % identical, the latter is
highly immunogenic in infected humans [34] and in ani-
mals [41]. Interestingly, TcCRT sequence is closer to plant
CRT (e.g. Arabidopsis thaliana) than to mammal CRT
(Weinberger et al., 2016, unpublished), thus explaining its
high immunogenicity. The parasite protein (recombinant
or native) bound to mammal tumor cells, could thus pro-
vide strong immunogenic signals that reveal the tumor
presence to an otherwise tolerant immune system.
In a large set of experimental animals treated with
rTcCRT, no clinical deleterious effects have been detected
by standard clinical veterinary criteria. rTcCRT, or derived
domains, are interesting immunological tools to be con-
sidered in more advanced preclinical trials (e.g. rTcCRT
and C1 binding to human mammary tumor cell lines and
its opsonizing consequences).
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Conclusions
Translocated/externalized native Trypanosoma cruzi calreti-
culin is responsible for at least an important part of the anti
mammary tumor effect of the experimental infection with
this parasite. Highly immunogenic recombinant TcCRT
largely reproduces this effect mainly by capturing comple-
ment C1 on the tumor cell surface, where a danger opson-
izing signal is thus generated. Altogether, these results allow
us to propose that an extremely relevant alteration in the
tumor microenvironment is thus accomplished. The pres-
ence of the tumor cells is thus revealed to the immune
system, with likely generation of an anamnestic systemic
immune response. These results identify recombinant
TcCRT or domains thereof, as interesting tools for further
preclinical studies in mammary cancer (i.e. tissue specificity
of the parasite chaperone, signal transduction pathways
involved, rTcCRT opsonization of human tumor cell lines).
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